ZA878183B - Ifosphamide lyophilisate and process for its preparation - Google Patents

Ifosphamide lyophilisate and process for its preparation

Info

Publication number
ZA878183B
ZA878183B ZA878183A ZA878183A ZA878183B ZA 878183 B ZA878183 B ZA 878183B ZA 878183 A ZA878183 A ZA 878183A ZA 878183 A ZA878183 A ZA 878183A ZA 878183 B ZA878183 B ZA 878183B
Authority
ZA
South Africa
Prior art keywords
ifosphamide
lyophilisate
preparation
ifosfamide
weight
Prior art date
Application number
ZA878183A
Other languages
English (en)
Inventor
Sauerbier Dieter
Dammann Uwe-Peter
Isaac Otto
Original Assignee
Asta Pharma Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Pharma Aktiengesellschaft filed Critical Asta Pharma Aktiengesellschaft
Publication of ZA878183B publication Critical patent/ZA878183B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Amplifiers (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Control Of El Displays (AREA)
  • Diaphragms For Electromechanical Transducers (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
ZA878183A 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation ZA878183B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE3637089 1986-10-31

Publications (1)

Publication Number Publication Date
ZA878183B true ZA878183B (en) 1988-05-02

Family

ID=6312873

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA878183A ZA878183B (en) 1986-10-31 1987-10-30 Ifosphamide lyophilisate and process for its preparation

Country Status (25)

Country Link
EP (1) EP0265812B1 (pm)
JP (1) JPS63159319A (pm)
KR (1) KR900003491B1 (pm)
AT (1) ATE55250T1 (pm)
AU (1) AU598602B2 (pm)
CA (1) CA1314231C (pm)
DD (1) DD262582A5 (pm)
DE (1) DE3764235D1 (pm)
DK (1) DK169308B1 (pm)
EG (1) EG18333A (pm)
ES (1) ES2017982B3 (pm)
FI (1) FI87140C (pm)
GE (1) GEP19971025B (pm)
GR (1) GR3000708T3 (pm)
HU (1) HU197987B (pm)
IL (1) IL84312A (pm)
IN (1) IN168119B (pm)
LV (1) LV10051B (pm)
MX (1) MX8958A (pm)
NO (1) NO873860L (pm)
PT (1) PT86032B (pm)
RU (1) RU1836079C (pm)
UA (1) UA11075A (pm)
YU (1) YU197387A (pm)
ZA (1) ZA878183B (pm)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0334083B1 (de) * 1988-03-19 1991-07-24 ASTA Pharma Aktiengesellschaft Ifosfamid-Mesna-Lyophilisat und Verfahren zu dessen Herstellung
US5227373A (en) * 1991-10-23 1993-07-13 Bristol-Myers Squibb Co. Lyophilized ifosfamide compositions
WO1995007083A1 (en) * 1993-09-10 1995-03-16 F.H. Faulding & Co. Limited Ifosfamide lyophilisate composition
DE19529057B4 (de) * 1995-08-08 2007-12-13 Baxter Healthcare S.A. Ifosfamid-Lyophilisat-Zubereitungen
CA2322796A1 (en) * 1998-03-03 1999-09-10 Eli Lilly & Company Pharmaceutical compositions containing the phospholipase inhibitor sodium ¬¬3-(2-amino-1,2-dioxoethyl)-2-ethyl-1-phenylmethyl)-1h-indol-4-yl|oxy|acetate
KR101037313B1 (ko) * 2002-09-05 2011-05-26 바라트 쎄럼스 앤드 백신스 리미티드 메스나를 함유하는 안정한 액체 옥스아자포스포린 조성물
DE60332385D1 (de) * 2002-12-02 2010-06-10 Bharat Serums & Vaccines Ltd Ifosfamid-zusammensetzungen zur parenteralen verabreichung und verfahren für ihre herstellung
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
EP2071917B1 (en) * 2006-09-29 2012-11-21 Infa S.A. Packaging system for pharmaceutical compositions and kit for intravenous administration
CN105900385B (zh) * 2014-12-04 2019-08-27 华为技术有限公司 在数据通信网中的负载分配

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3732340A (en) * 1966-07-11 1973-05-08 Asta Werke Ag Chem Fab N',o-propylene phosphoric acid ester diamides
DE2750207A1 (de) * 1977-05-09 1978-11-16 Walton J Smith Gefriergetrocknete zusammensetzungen, insbesondere gefriergetrocknete pharmazeutische praeparate und verfahren zu deren herstellung
EP0083439B1 (de) * 1981-12-31 1989-07-26 ASTA Pharma AG 4-Sulfido-oxazaphosphorine und deren Verwendung bei der Krebsbekämpfung und zur Immunsuppression
US4537883A (en) * 1982-11-12 1985-08-27 Mead Johnson & Company Lyophilized cyclophosphamide

Also Published As

Publication number Publication date
UA11075A (uk) 1996-12-25
HUT44932A (en) 1988-05-30
GEP19971025B (en) 1997-04-06
CA1314231C (en) 1993-03-09
PT86032B (pt) 1990-08-31
JPH0543684B2 (pm) 1993-07-02
PT86032A (de) 1987-11-01
JPS63159319A (ja) 1988-07-02
RU1836079C (ru) 1993-08-23
ES2017982B3 (es) 1991-03-16
NO873860D0 (no) 1987-09-15
FI874727L (fi) 1988-05-01
ATE55250T1 (de) 1990-08-15
DE3764235D1 (de) 1990-09-13
IL84312A0 (en) 1988-03-31
AU598602B2 (en) 1990-06-28
HU197987B (en) 1989-07-28
DK569687D0 (da) 1987-10-30
EG18333A (en) 1993-12-30
FI87140C (fi) 1992-12-10
EP0265812B1 (de) 1990-08-08
GR3000708T3 (en) 1991-10-10
LV10051B (en) 1995-06-20
KR900003491B1 (ko) 1990-05-21
LV10051A (lv) 1994-05-10
DD262582A5 (de) 1988-12-07
NO873860L (no) 1988-05-02
DK169308B1 (da) 1994-10-10
FI874727A0 (fi) 1987-10-27
EP0265812A1 (de) 1988-05-04
KR880004814A (ko) 1988-06-27
AU8052987A (en) 1988-05-05
DK569687A (da) 1988-05-01
MX8958A (es) 1993-12-01
FI87140B (fi) 1992-08-31
IL84312A (en) 1991-11-21
IN168119B (pm) 1991-02-09
YU197387A (en) 1988-12-31

Similar Documents

Publication Publication Date Title
EP0427247A3 (en) Pharmaceutical composition with r-alpha-lipoic acid or s-alpha-lipoic acid as the active ingredient
GR3007251T3 (pm)
EP0348808A3 (de) Neue Arzneimittelformulierung sowie Verfahren zu deren Herstellung
LU90949I2 (fr) Esters aminoalcohol d'acide thienylcarboxyliques leurs produits quaternaires leur préparation et l'utilisation de ces composés
GR3002377T3 (en) Ifosfamide-mesna-lyophilized composition and process to prepare it
DE3766200D1 (de) L-dopa enthaltendes arzneimittel.
GR3019388T3 (en) The use of buspirone for preparing a pharmaceutical composition for the treatment of alcohol abuse
PH23565A (en) Novel pyrimidinylpyrimidine derivatives and a plant disease protectant containing them as the active ingredient
ZA878183B (en) Ifosphamide lyophilisate and process for its preparation
ZA882449B (en) Dihydropyridinamides,a process for their preparation,and their use in medicaments
DK23490A (da) Implanteret antibiotisk tilberedning med reguleret frigivelse
ZA894667B (en) Process for the preparation of 2,6-dichlorodiphenyl-amino-acetic derivatives
IL82145A0 (en) Substituted thiacycloalkeno(3,2-b)pyridines,their preparation and pharmaceutical compositions containing them
GR3003638T3 (pm)
KR900700484A (ko) 1,4:3,6-디안히드로 헥시톨 잘산염의 아미노프로판올 유도체,그의 제법 및 약제로서의 그의 용도
CA2022323A1 (en) Excretion of potassium ion by prostanoic acid derivatives
DE3666041D1 (en) Process for preparing 4,5-dihydro-dithienol (3,4b:3'4'-e)-azepin-5,9-dione
IL83495A0 (en) Oxirane pseudooligosaccharides,a process for their preparation,and pharmaceutical preparations containing them
EP0415564A3 (en) Improvement of excretion of nonprotein nitrogen into the intestine by prostanoic acid derivaties
HUT46693A (en) Process for producing dioxabicyclo/3,3,0/oktanon-oxim-ethers and pharmaceutical compositions containing them as active components
AU1732888A (en) Stable 5-fluorouracil compositions
ZA883610B (en) A process for the preparation of 5-acylamino-2,4,6-triiodo-or tribromo-benzioc acid derivatives and the acid derivatives obtained by said process
IT1186793B (it) Frazione ottenuta da listeria monocytogenes avente attivita' terapeutica,procedimento per la sua preparazione e composioni farmaceutiche che la contengono